|
in vitro fertilization |
26 |
|
female |
15 |
|
infertility |
15 |
|
polycystic ovary syndrome |
15 |
|
pregnancy |
15 |
|
vitamin d |
15 |
|
humans |
14 |
|
ovarian response |
14 |
|
anti-müllerian hormone |
13 |
|
anti-mullerian hormone |
12 |
|
antral follicle count |
12 |
|
dysglycaemia |
12 |
|
ciliary beat frequency |
11 |
|
fallopian tube |
11 |
|
fatty liver disease |
11 |
|
frozen embryo transfer |
11 |
|
ivf |
11 |
|
mafld (metabolic associated fatty liver disease) |
11 |
|
mifepristone |
11 |
|
obesity |
11 |
|
overweight |
11 |
|
population based study |
11 |
|
tubal ectopic pregnancy |
11 |
|
ulipristal acetate |
10 |
|
emergency contraception |
9 |
|
male |
9 |
|
muscular contraction |
9 |
|
pregnancy rate |
9 |
|
adrenomedullin |
8 |
|
adrenomedullin - genetics - metabolism |
8 |
|
calcitonin receptor-like protein |
8 |
|
cell communication - physiology |
8 |
|
cell line |
8 |
|
cilia - metabolism - physiology |
8 |
|
cumulative live birth rate |
8 |
|
epithelium - metabolism - physiology |
8 |
|
fallopian tubes - metabolism |
8 |
|
gene expression regulation - drug effects |
8 |
|
hormones - metabolism - pharmacology |
8 |
|
intracellular signaling peptides and proteins - genetics - metabolism |
8 |
|
intrauterine insemination |
8 |
|
letrozole |
8 |
|
live birth rate |
8 |
|
membrane proteins - genetics - metabolism |
8 |
|
menstrual cycle - genetics - metabolism - physiology |
8 |
|
miscarriage |
8 |
|
models, biological |
8 |
|
receptor activity-modifying proteins |
8 |
|
receptors, calcitonin - genetics - metabolism |
8 |
|
spermatozoa |
8 |
|
spermatozoa - metabolism - physiology |
8 |
|
age‐specific reference range |
7 |
|
anti‐müllerian hormone |
7 |
|
automated chemiluminescence assay |
7 |
|
chemokines |
7 |
|
chinese women |
7 |
|
endometrial regeneration |
7 |
|
endometrial stem cells |
7 |
|
inflammatory cytokines |
7 |
|
nasal ciliated epithelium |
7 |
|
ovarian sensitivity index |
7 |
|
pain relief |
7 |
|
randomized controlled trial |
7 |
|
advanced glycation end-products |
6 |
|
age |
6 |
|
apoptosis |
6 |
|
biological markers - blood |
6 |
|
cell biology |
6 |
|
cell signaling |
6 |
|
chemotherapy |
6 |
|
endometrium |
6 |
|
fasting glucose |
6 |
|
gestational trophoblastic neoplasia |
6 |
|
leptin |
6 |
|
leptin receptor |
6 |
|
levonorgestrel |
6 |
|
mapk signaling |
6 |
|
medical abortion |
6 |
|
metabolic syndrome |
6 |
|
misoprostol |
6 |
|
molar pregnancy |
6 |
|
obstetrics and gynecology |
6 |
|
olfactomedin-1 |
6 |
|
oocyte retrieval |
6 |
|
oral glucose tolerance test |
6 |
|
ovarian reserve |
6 |
|
pregnancy complications |
6 |
|
progesterone receptor |
6 |
|
soluble receptor of advanced glycation end-products |
6 |
|
stem cell-microenvironment interactions |
6 |
|
stromal cells |
6 |
|
threatened miscarriage |
6 |
|
wnt-signaling |
6 |
|
25-hydroxyvitamin d |
5 |
|
adiposity |
5 |
|
adolescent |
5 |
|
adult |
5 |
|
androgen |
5 |
|
anti-mullerian hormone - blood |
5 |
|
anti‐mullerian hormone |
5 |
|
b cells |
5 |
|
birth control medical sciences |
5 |
|
cancer |
5 |
|
ciliary beat |
5 |
|
conscious sedation |
5 |
|
down syndrome |
5 |
|
down syndrome - blood |
5 |
|
embryo cryopreservation |
5 |
|
embryo transfer |
5 |
|
endometrial attachment |
5 |
|
endothelial cell |
5 |
|
fertility preservation |
5 |
|
fertilization |
5 |
|
fertilization in vitro |
5 |
|
first trimester |
5 |
|
frozen-thawed embryo transfer |
5 |
|
gestational age |
5 |
|
glycodelin |
5 |
|
gonadotrophin dosing |
5 |
|
human fallopian tube |
5 |
|
hyaluronic acid |
5 |
|
immune tolerance |
5 |
|
in vitro fertilsation |
5 |
|
ishikawa cell line |
5 |
|
l-selectin |
5 |
|
live birth |
5 |
|
maternal age |
5 |
|
maternal-fetal interface |
5 |
|
medical sciences |
5 |
|
middle aged |
5 |
|
natural cycle |
5 |
|
natural killer cell |
5 |
|
oocyte cryopreservation |
5 |
|
oral progestogen |
5 |
|
ovarian response prediction index |
5 |
|
ovulation induction |
5 |
|
pregnancy - blood |
5 |
|
primary endometrial cell culture |
5 |
|
progesterone |
5 |
|
progesterone elevation |
5 |
|
sperm cryopreservation |
5 |
|
transfer medium |
5 |
|
trophoblast |
5 |
|
vaginal bleeding |
5 |
|
abortifacient agents, nonsteroidal - pharmacokinetics |
4 |
|
abortion, induced - methods |
4 |
|
acetic acid |
4 |
|
acetic acid - pharmacokinetics |
4 |
|
acrosome reaction |
4 |
|
acrosome reaction - drug effects - physiology |
4 |
|
anti-mullerian hormone - analysis - blood |
4 |
|
anti-möllerian hormone |
4 |
|
anti-obesity drugs |
4 |
|
antimullerian hormone |
4 |
|
assisted reproductive technologies |
4 |
|
attitude |
4 |
|
automated chemiluminescence |
4 |
|
bologna criteria |
4 |
|
capacitation |
4 |
|
cell count |
4 |
|
chinese couple |
4 |
|
chlortetracycline - metabolism - pharmacology |
4 |
|
combined injectable contraceptive |
4 |
|
combined oral contraceptive |
4 |
|
concern |
4 |
|
contraceptives, oral, combined - pharmacology |
4 |
|
controlled ovarian stimulation |
4 |
|
counselling |
4 |
|
cryopreservation |
4 |
|
cumulative live birth |
4 |
|
cumulative live-birth |
4 |
|
dehydroepiandrosterone |
4 |
|
dhea |
4 |
|
dilution linearity |
4 |
|
diminished ovarian reserve |
4 |
|
dna integrity |
4 |
|
dna meiotic recombinase 1 (dmc1) |
4 |
|
dydrogesterone |
4 |
|
endocrinology |
4 |
|
endocrinology pharmacy and pharmacology |
4 |
|
endometrial injury |
4 |
|
endometrial polyp |
4 |
|
enzyme-linked immunosorbent assay |
4 |
|
family planning service provision |
4 |
|
follicle stimulating hor mone/administration & dosage |
4 |
|
follicle stimulating hormone/therapeutic use |
4 |
|
follicle-stimulating hormone |
4 |
|
freeze-thaw stability |
4 |
|
gonadotropins/administration & dosage |
4 |
|
gonadotropins/therapeutic use |
4 |
|
granulosa cells |
4 |
|
hcg |
4 |
|
homozygous frameshift mutation |
4 |
|
hspa2 |
4 |
|
human spermatozoa |
4 |
|
human study |
4 |
|
hydrogen-ion concentration |
4 |
|
hyperprolactinemia |
4 |
|
hypogonadotrophic hypogonadism |
4 |
|
hysteroscopy |
4 |
|
immunoassay |
4 |
|
in vitro activation |
4 |
|
in vitro fertilisation |
4 |
|
in-vitro fertilisation |
4 |
|
infertility - blood - diagnosis - therapy |
4 |
|
inhibin b |
4 |
|
inhibins - blood |
4 |
|
insemination, artificial - methods |
4 |
|
interleukin 6 |
4 |
|
intervention |
4 |
|
intrauterine devices, medicated |
4 |
|
intrauterine lidocaine |
4 |
|
isolated polycystic ovaries |
4 |
|
leptin - metabolism - pharmacology |
4 |
|
levonorgestrel intrauterine system |
4 |
|
lidocaine gel |
4 |
|
live-birth |
4 |
|
luteal phase support |
4 |
|
macrophages |
4 |
|
male germline-specific protein |
4 |
|
maps |
4 |
|
meiosis prophase i |
4 |
|
mental health |
4 |
|
metformin |
4 |
|
method comparison |
4 |
|
methylation |
4 |
|
misoprostol - pharmacokinetics |
4 |
|
motility |
4 |
|
mouse study |
4 |
|
natural cycles |
4 |
|
natural family planning |
4 |
|
nonobstructive azoospermia |
4 |
|
normal ovarian responders |
4 |
|
normal saline |
4 |
|
obstetrics and gynecology medical sciences |
4 |
|
oligomenorrhea - blood - diagnosis - etiology |
4 |
|
oocyte |
4 |
|
oogenesis |
4 |
|
orlistat |
4 |
|
ovarian response markers |
4 |
|
ovary/drug effects |
4 |
|
ovulation induction - adverse effects - methods |
4 |
|
pachynema progression |
4 |
|
pharmacokinetics |
4 |
|
pi3k/pten signaling |
4 |
|
poor ovarian response |
4 |
|
poor responders |
4 |
|
pre-pregnancy |
4 |
|
precision |
4 |
|
pregnancy outcome |
4 |
|
preimplantation genetic testing |
4 |
|
premature ovarian failure |
4 |
|
premature ovarian insufficiency |
4 |
|
primordial follicles |
4 |
|
progestins - pharmacology |
4 |
|
progestogen |
4 |
|
progestogen-only injectable |
4 |
|
progestogen-only pill |
4 |
|
prospective studies |
4 |
|
protamination |
4 |
|
randomised trial |
4 |
|
reproductive medicine |
4 |
|
saline contrast sonohysterography |
4 |
|
saline infusion sonogram |
4 |
|
semen - metabolism |
4 |
|
sexual dimorphism |
4 |
|
sibutramine |
4 |
|
spaca3 |
4 |
|
sperm capacitation - drug effects |
4 |
|
sperm motility - drug effects - physiology |
4 |
|
sperm selection |
4 |
|
spermatogenesis |
4 |
|
spermatozoa - drug effects - metabolism - physiology |
4 |
|
stem cell niche |
4 |
|
t cell |
4 |
|
testosterone |
4 |
|
transcutaneous electrical nerve stimulation |
4 |
|
transvaginal oocyte retrieval |
4 |
|
vaginal misoprostol |
4 |
|
whole-exome sequencing |
4 |
|
wnt/β-catenin signaling |
4 |
|
zona pellucida |
4 |
|
3-dimensional |
3 |
|
4930432k21rik |
3 |
|
adrenomedullin - blood - genetics - physiology |
3 |
|
adverse pregnancy outcomes |
3 |
|
andrology |
3 |
|
antiobesity drugs |
3 |
|
arthritis |
3 |
|
arthritis, rheumatoid |
3 |
|
box trainer |
3 |
|
caesarean scar |
3 |
|
cilia - physiology |
3 |
|
complications |
3 |
|
continuous companion support |
3 |
|
contraceptive agents, female |
3 |
|
contraceptives |
3 |
|
contraceptives, oral, combined |
3 |
|
contraceptives, oral, hormonal |
3 |
|
corifollitropin alfa |
3 |
|
cost |
3 |
|
covid-19 pandemic |
3 |
|
creb |
3 |
|
data entry |
3 |
|
data precision |
3 |
|
early pregnancy assessment clinic |
3 |
|
ectopic pregnancy |
3 |
|
erectile dysfunction |
3 |
|
ethnicity |
3 |
|
fallopian tubes - physiology |
3 |
|
female sexual dysfunction |
3 |
|
fertility restoration |
3 |
|
fet cycles |
3 |
|
hormonal |
3 |
|
hormone replacement therapy |
3 |
|
in-vitro fertilization |
3 |
|
infertility in-vitro fertilization |
3 |
|
intercycle variation |
3 |
|
labyrinthine zone |
3 |
|
laparoscopy |
3 |
|
lorcaserin |
3 |
|
lupus erythematosus |
3 |
|
lupus erythematosus, systemic |
3 |
|
meiosis |
3 |
|
menstrual pattern |
3 |
|
mtor |
3 |
|
nausea and vomiting in pregnancy |
3 |
|
oral |
3 |
|
ovarian stimulation |
3 |
|
phentermine/topiramate |
3 |
|
placenta |
3 |
|
post-ovulatory |
3 |
|
pre-ovulatory |
3 |
|
preconception |
3 |
|
pregnancy outcomes |
3 |
|
pregnancy, tubal - blood - etiology - physiopathology |
3 |
|
prepregnancy |
3 |
|
public service |
3 |
|
quality of life. |
3 |
|
recombination |
3 |
|
retrospective cohort |
3 |
|
rheumatic diseases |
3 |
|
rheumatoid |
3 |
|
semen analysis |
3 |
|
stimulated cycles |
3 |
|
systemic |
3 |
|
tlr5 |
3 |
|
ubiquitination |
3 |
|
waiting time |
3 |
|
willingness to pay |
3 |
|
acupuncture |
2 |
|
amh |
2 |
|
anovulatory subfertility |
2 |
|
anti-oestrogen |
2 |
|
aromatase inhibitor |
2 |
|
atosiban |
2 |
|
automated assays |
2 |
|
choriocarcinoma |
2 |
|
choriocarcinoma - metabolism |
2 |
|
companion diagnostic |
2 |
|
contraceptives, oral |
2 |
|
contraceptives, postcoital |
2 |
|
controlled ovarian hyperstimulation |
2 |
|
copper intrauterine device |
2 |
|
de novo mutation |
2 |
|
dopamine agonist |
2 |
|
droplet digital pcr |
2 |
|
follitropin delta |
2 |
|
gonadal mosaicism |
2 |
|
gonadotrophin |
2 |
|
gonosomal mosaicism |
2 |
|
hormonal contraception |
2 |
|
hydatidiform mole |
2 |
|
hydatidiform mole - metabolism |
2 |
|
immunoassays |
2 |
|
immunohistochemistry |
2 |
|
infertility. |
2 |
|
insulin resistance |
2 |
|
insulin sensitivity |
2 |
|
ipd meta-analysis |
2 |
|
leptin - biosynthesis |
2 |
|
medical treatment |
2 |
|
missed miscarriage |
2 |
|
non-inferiority randomised trial |
2 |
|
obstetric outcomes |
2 |
|
ovarian drilling |
2 |
|
parental mosaicism |
2 |
|
pcos |
2 |
|
personalised medicine |
2 |
|
placenta - metabolism |
2 |
|
placental site trophoblastic tumor |
2 |
|
protein isoforms |
2 |
|
pulsatile gnrh |
2 |
|
receptors, cell surface - biosynthesis |
2 |
|
receptors, leptin |
2 |
|
recurrence risk |
2 |
|
reverse transcriptase polymerase chain reaction |
2 |
|
stein-leventhal syndrome. |
2 |
|
up-regulation |
2 |
|
uterine contraction |
2 |
|
uterine neoplasms - metabolism |
2 |
|
weight management |
2 |
|
早孕 |
2 |
|
米索前列醇 (misoprostol) |
2 |
|
米非司酮 (mifepristone) |
2 |
|
舌下含服 (sublingual swallowing) |
2 |
|
药物流产 |
2 |
|
abortion |
1 |
|
adipocyte |
1 |
|
administration, intravaginal |
1 |
|
anesthetics, local - administration & dosage |
1 |
|
anovulation - drug therapy |
1 |
|
antineoplastic combined chemotherapy protocols - adverse effects |
1 |
|
artificial insemination |
1 |
|
asia-oceania |
1 |
|
asian women |
1 |
|
assisted conception |
1 |
|
assisted reproduction |
1 |
|
assisted reproductive technology |
1 |
|
automated chemiluminescence immunoassay |
1 |
|
beta-adrenergic receptor signaling |
1 |
|
biopsy, needle - adverse effects |
1 |
|
carmustine - adverse effects |
1 |
|
case-control studies |
1 |
|
cervical punch biopsy |
1 |
|
cisplatin - adverse effects |
1 |
|
colposcopy |
1 |
|
colposcopy - adverse effects |
1 |
|
combination chemotherapy |
1 |
|
combined oral contraceptive pills |
1 |
|
contraception |
1 |
|
contraception - statistics & numerical data |
1 |
|
contraceptive benefits |
1 |
|
contraceptive failure |
1 |
|
contraceptive safety |
1 |
|
corpus luteum |
1 |
|
cumulative ongoing pregnancy |
1 |
|
cyclo-oxygenase inhibitors |
1 |
|
dacarbazine - adverse effects |
1 |
|
dna primers |
1 |
|
double-blind method |
1 |
|
endometrial effect |
1 |
|
endometrioid adenocarcinoma |
1 |
|
enzyme-linked immunosorbent assay (elisa) |
1 |
|
family planning services |
1 |
|
female sterilization |
1 |
|
follicle stimulating hormone, human - therapeutic use |
1 |
|
gels |
1 |
|
gene expression profiling |
1 |
|
health services accessibility |
1 |
|
hong kong - epidemiology |
1 |
|
hormonal emergency contraception |
1 |
|
human |
1 |
|
hyperandrogenism - blood - complications - epidemiology |
1 |
|
implantation |
1 |
|
induced |
1 |
|
infant, newborn |
1 |
|
infertility, female - drug therapy |
1 |
|
injectable contraceptive |
1 |
|
international standard |
1 |
|
intrauterine contraceptive device |
1 |
|
lidocaine - administration & dosage |
1 |
|
lignocaine gel |
1 |
|
lipogenesis |
1 |
|
lipolysis |
1 |
|
liver neoplasms - drug therapy - secondary |
1 |
|
long-acting reversible contraception |
1 |
|
maspin |
1 |
|
melanoma |
1 |
|
melanoma - drug therapy - secondary |
1 |
|
metabolic syndrome x - blood - epidemiology - etiology |
1 |
|
metastasis |
1 |
|
microphthalmos |
1 |
|
microphthalmos - chemically induced |
1 |
|
npy |
1 |
|
obesity - blood - complications - epidemiology |
1 |
|
ovulation induction - methods |
1 |
|
pain - prevention & control |
1 |
|
pain measurement |
1 |
|
pilot projects |
1 |
|
polycystic ovary syndrome - blood - complications - epidemiology |
1 |
|
postcoital contraceptive agents |
1 |
|
pre-eclampsia - metabolism |
1 |
|
preeclampsia |
1 |
|
pregnancy complications, neoplastic - drug therapy |
1 |
|
pregnancy trimester, first - drug effects |
1 |
|
pregnancy trimester, second - drug effects |
1 |
|
prevalence |
1 |
|
protein isoforms - biosynthesis |
1 |
|
quality of life |
1 |
|
questionnaires |
1 |
|
reference preparation |
1 |
|
reproductive health |
1 |
|
retrospective studies |
1 |
|
risk factors |
1 |
|
scotland - epidemiology |
1 |
|
sexual function |
1 |
|
sexuality |
1 |
|
skin neoplasms - drug therapy - pathology |
1 |
|
sterilization, tubal |
1 |
|
suction evacuation |
1 |
|
tamoxifen - adverse effects |
1 |
|
termination of pregnancy |
1 |
|
topical xylocaine gel |
1 |
|
vitamin d - analogs & derivatives - blood |
1 |
|
vitamin d deficiency - blood - complications - epidemiology |
1 |
|
young adult |
1 |
